A bibliometric study on microenvironment-mediated drug resistance in interventional liver cancer treatment
Authors:
Open Access
- 24 November 2025
- journal article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2157
Abstract
Microenvironment-driven drug resistance is a principal barrier to durable response after transarterial chemoembolisation, ablation or radioembolisation for hepatocellular carcinoma, yet the global structure of scholarship linking these domains remains undefined. This bibliometric analysis mapped 25-year publication trends, thematic evolution and collaboration networks at the intersection of interventional oncology, tumour microenvironment and therapeutic resistance. Web of Science Core Collection was searched (1 January 2000–31 December 2024) for records simultaneously referencing liver cancer, interventional therapy, microenvironmental descriptors and resistance terms. After dual-review screening, 939 articles and reviews were retained. Annual output, citation impact and Bradford-zone distributions were generated with bibliometrix 4.2.1. Bradford-zone analysis refers to the distribution of journal productivity, with journals in the first zone representing core literature, and those in subsequent zones reflecting peripheral or niche studies. This method helps assess the concentration of research in key journals and identifies areas of growth in the literature; co-authorship, journal-coupling and keyword-co-occurrence networks were rendered in VOSviewer 1.6.20. Workflow reproducibility was confirmed on a 5% subsample and by comparing fractional with full counting. Yearly publications rose from two in 2000 to 130 in 2024, amassing 36 095 citations (mean 38.4 per item). Output spikes in 2013, 2019 and 2021 paralleled seminal reports on hypoxia-driven angiogenesis, CAF activation, and COVID-19-related endothelial dysfunction. The pathophysiological mechanisms of COVID-19-induced endothelial injury, including cytokine-mediated endothelial dysfunction, have been implicated in compromising loco-regional therapies, contributing to resistance mechanisms that affect the efficacy of embolic treatments. China produced 47.3% of documents and sat at the nexus of global collaboration, with prominent links to the United States, Japan and South Korea. Cancer Research, Hepatology and Journal of Hepatology led citation rankings. Keyword overlays revealed a chronological shift from procedure-centric terms to microenvironmental and immunologic nodes—“angiogenesis”, “immune checkpoint”, “nanoparticles”—after 2017. Trend-topic mapping documented a transition from device optimisation toward mechanism-informed combination regimens incorporating anti-VEGF or PD-1 blockade. Research on microenvironment-mediated resistance in interventional liver-cancer therapy has expanded rapidly and pivoted toward molecularly targeted, immune-augmented strategies, driven chiefly by high-volume Chinese centres and trans-Pacific partnerships. Priorities now include single-cell analytics, radiomics-guided adaptive embolisation and multinational trials of combination therapy.Keywords
This publication has 43 references indexed in Scilit:
- PD1+ Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carcinomaCancer Immunology, Immunotherapy, 2025
- Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinomaJournal of Controlled Release, 2024
- Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor ThrombosisCardioVascular and Interventional Radiology, 2024
- Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivationCell Reports Medicine, 2024
- Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeuticsEnvironmental Toxicology, 2024
- Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumoursClinical and Translational Medicine, 2024
- HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolizationDigestive and Liver Disease, 2023
- Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinomaActa Biomaterialia, 2022
- Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinomaHepatology Communications, 2022
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaJournal of Hepatology, 2022